85. 特発性間質性肺炎
［臨床試験数：514，薬物数：377（DrugBank：108），標的遺伝子数：97，標的パスウェイ数：204］
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03720483 (ClinicalTrials.gov) | January 2022 | 18/7/2018 | Inhaled NAC in Treatment of IPF | Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Drug: N-acetyl cysteine then Placebo;Drug: Placebo then N-acetyl cysteine | University of Colorado, Denver | NULL | Not yet recruiting | 40 Years | 75 Years | All | 50 | Phase 1;Phase 2 | United States |
| 2 | EUCTR2019-002709-23-DE (EUCTR) | 18/12/2020 | 31/01/2020 | A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 inparticipants with idiopathic pulmonary fibrosis | A randomized, double-blind, dose-ranging, placebo-controlled Phase 2aevaluation of the safety, tolerability and pharmacokinetics of PLN-74809 inparticipants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-000 | Pliant Therapeutics Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 84 | Phase 2 | United States;France;Canada;Belgium;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| 3 | NCT04300920 (ClinicalTrials.gov) | November 20, 2020 | 6/3/2020 | Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial | Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial | Idiopathic Pulmonary Fibrosis | Drug: N-acetyl cysteine;Drug: Placebo | Weill Medical College of Cornell University | University of Virginia;University of Michigan;Pulmonary Fibrosis Foundation;University of Washington;National Heart, Lung, and Blood Institute (NHLBI);Three Lakes Foundation | Not yet recruiting | 40 Years | N/A | All | 200 | Phase 3 | United States |
| 4 | EUCTR2019-002709-23-GB (EUCTR) | 06/11/2020 | 24/01/2020 | A study to assess the efficacy, safety and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis | A randomized, double-blind, dose-ranging, placebo-controlled Phase 2a evaluation of the safety, tolerability and pharmacokinetics of PLN-74809 in participants with idiopathic pulmonary fibrosis (IPF) (INTEGRIS-IPF) | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-000 Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not available Other descriptive name: PLN-74809-000 Product Name: PLN-74809 Product Code: PLN-74809 INN or Proposed INN: Not Available Other descriptive name: PLN-74809-000 | Pliant Therapeutics Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | Phase 2 | United States;France;Canada;Belgium;Australia;Netherlands;Germany;New Zealand;Italy;United Kingdom | ||
| 5 | EUCTR2019-004167-45-SK (EUCTR) | 02/11/2020 | 11/08/2020 | A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 taken orally. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Slovakia;Greece;Finland;Spain;Ukraine;Austria;Russian Federation;Chile;United Kingdom;Italy;Hungary;Mexico;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;Japan;China;Korea, Republic of;Czechia | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04598919 (ClinicalTrials.gov) | November 1, 2020 | 15/9/2020 | Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis | Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Drug: Saracatinab;Drug: Placebo | National Jewish Health | Yale University;Icahn School of Medicine at Mount Sinai;AstraZeneca;National Center for Advancing Translational Science (NCATS) | Recruiting | 40 Years | N/A | All | 100 | Phase 1;Phase 2 | United States |
| 7 | NCT04262167 (ClinicalTrials.gov) | October 22, 2020 | 6/2/2020 | Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis | A Phase I, Randomized Study of the Safety and Efficacy of Intravenous Delivery of Lung Spheroid Stem Cells (LSCs) in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: Lung Spheroid Stem Cells 100 million;Biological: Lung Spheroid Stem Cells 200 million | University of North Carolina, Chapel Hill | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 50 Years | 80 Years | All | 24 | Phase 1 | United States |
| 8 | EUCTR2020-000697-22-DK (EUCTR) | 13/10/2020 | 14/08/2020 | A study to compare the use of Pamrevlumab with Placebo in patients with Idiopathic Pulmonary Fibrosis. | Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB | FibroGen, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 340 | Phase 3 | Serbia;Spain;Ukraine;Ireland;Lebanon;Colombia;United Kingdom;Italy;India;France;Czech Republic;Hungary;Mexico;Poland;Brazil;Dominican Republic;Peru;Denmark;Georgia;Netherlands;Germany | ||
| 9 | EUCTR2020-000697-22-DE (EUCTR) | 13/10/2020 | 05/08/2020 | A study to compare the use of Pamrevlumab with Placebo in patients with Idiopathic Pulmonary Fibrosis. | Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB | FibroGen, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 340 | Phase 3 | Serbia;Spain;Ukraine;Lebanon;Ireland;Colombia;United Kingdom;Italy;India;France;Czech Republic;Hungary;Mexico;Poland;Belgium;Brazil;Dominican Republic;Peru;Denmark;Bulgaria;Georgia;Norway;Netherlands;Germany | ||
| 10 | EUCTR2019-004167-45-DK (EUCTR) | 27/08/2020 | 12/06/2020 | A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 18 mg taken orally. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim B.V. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | Spain;Ukraine;Chile;Russian Federation;Italy;France;Australia;Denmark;Netherlands;China;Korea, Republic of;Finland;Austria;United Kingdom;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Germany;Japan;Slovakia;Greece;United States | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2019-004167-45-PL (EUCTR) | 24/08/2020 | 14/07/2020 | A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 taken orally. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Greece;Finland;Spain;Ukraine;Austria;Russian Federation;Chile;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;Japan;China;Korea, Republic of | ||
| 12 | EUCTR2019-004167-45-GB (EUCTR) | 19/08/2020 | 24/06/2020 | A study to test how taking BI 1015550 for 12 weeks affects lung function in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Slovakia;Greece;Finland;Spain;Ukraine;Austria;Russian Federation;Chile;Italy;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;Japan;China;Korea, Republic of | ||
| 13 | EUCTR2019-004167-45-HU (EUCTR) | 17/08/2020 | 24/06/2020 | A study to test how taking BI 1015550 for 12 weeks affects lung function in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 18 mg taken orally b.i.d. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Greece;Finland;Spain;Austria;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Canada;Poland;Australia;Denmark;Netherlands;Germany;China;Japan;Korea, Republic of | ||
| 14 | EUCTR2019-004167-45-DE (EUCTR) | 30/07/2020 | 22/06/2020 | A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 taken orally. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Slovakia;Greece;Finland;Spain;Ukraine;Austria;Russian Federation;Chile;United Kingdom;Italy;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;Japan;China;Korea, Republic of | ||
| 15 | EUCTR2019-004998-34-GB (EUCTR) | 16/07/2020 | 04/02/2020 | A clinical study to investigate the safety and effects of a new drug called BLD-2660 in patients with Idiopathic Pulmonary Fibrosis | A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic Pulmonary Fibrosis - B-2660-203 | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BLD-2660 Product Code: BLD-2660 INN or Proposed INN: None Other descriptive name: BLD-2660 | Blade Therapeutics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2019-004167-45-NL (EUCTR) | 09/07/2020 | 12/05/2020 | A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 18 mg taken orally b.i.d. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Slovakia;Greece;Spain;Ukraine;Chile;Russian Federation;Italy;France;Denmark;Australia;Netherlands;China;Korea, Republic of;Finland;Austria;United Kingdom;Czech Republic;Hungary;Mexico;Canada;Argentina;Poland;Germany;Japan | ||
| 17 | EUCTR2020-000697-22-HU (EUCTR) | 08/07/2020 | 22/05/2020 | A study to compare the use of Pamrevlumab with Placebo in patients with Idiopathic Pulmonary Fibrosis. | Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Name: Pamrevlumab Product Code: FG-3019 INN or Proposed INN: PAMREVLUMAB | FibroGen, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 340 | Phase 3 | Serbia;Spain;Ukraine;Lebanon;Ireland;Colombia;Italy;United Kingdom;India;France;Hungary;Czech Republic;Mexico;Poland;Belgium;Brazil;Dominican Republic;Peru;Denmark;Bulgaria;Georgia;Norway;Netherlands;Germany | ||
| 18 | EUCTR2020-000822-24-GB (EUCTR) | 06/07/2020 | 03/04/2020 | To investigate the safety, effectiveness and fate of study drug C21 in people with chronic scarring lung disease characterised by a progressive and irreversible decline in lung function. | A Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy and Pharmacokinetics of C21 in Subjects with Idiopathic Pulmonary Fibrosis - C21 in IPF | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: C21 INN or Proposed INN: C21 Other descriptive name: 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt | Vicore Pharma AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | Ukraine;United Kingdom | ||
| 19 | EUCTR2019-003992-21-BE (EUCTR) | 03/07/2020 | 04/05/2020 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis | Pulmonary Fibrosis MedDRA version: 21.0;Level: PT;Classification code 10037383;Term: Pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 21.1;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BMS-986278 Product Code: BMS-986278 INN or Proposed INN: LPA1 Other descriptive name: BMS-986278 Product Name: BMS-986278 Product Code: BMS-986278 INN or Proposed INN: LPA1 Other descriptive name: BMS-986278 | Bristol-Myers Squibb International Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 360 | Phase 2 | United States;Spain;Chile;Israel;United Kingdom;Italy;France;Mexico;Canada;Argentina;Belgium;Brazil;Australia;Germany;Japan;Korea, Republic of | ||
| 20 | EUCTR2020-000041-14-GB (EUCTR) | 19/06/2020 | 08/07/2020 | Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole | The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial - TIPAL | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Lansoprazole Product Name: Lansoprazole INN or Proposed INN: lansoprazole Other descriptive name: N/A | Norfolk and Norwich University Hospitals NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 298 | Phase 3 | United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2018-002664-73-IE (EUCTR) | 25/05/2020 | 20/12/2018 | Clinical study of the inhaled research drug TD139 to test its effectiveness and safety in patients with a serious scarring disease of the lung over 52 weeks. | GALACTIC-1- A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks | patients with idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10067761;Term: Exacerbation of idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Product Name: TD139 Product Code: TD139 INN or Proposed INN: TD139 Other descriptive name: DEX284 Product Name: TD139 Product Code: TD139 INN or Proposed INN: TD139 Other descriptive name: DEX284 | Galecto Biotech AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2 | United States;France;Canada;Spain;Poland;Belgium;Ireland;Israel;Germany;United Kingdom;Italy | ||
| 22 | EUCTR2019-003571-19-GB (EUCTR) | 21/05/2020 | 27/02/2020 | A multicentre, double blind, placebo controlled, crossover trial of morphine sulphate sulfate for the treatment of PulmonAry Fibrosis Cough (PAciFy Cough Trial) | PAciFy Cough: A multicentre, double blind, placebo controlled, crossover trial of morphine sulfate for the treatment of PulmonAry Fibrosis Cough - PACIFY Cough | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Morphine Sulfate Product Name: Morphine Sulfate INN or Proposed INN: morphine sulfate | Royal Brompton and Harefield NHS Foundation Trust | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 44 | Phase 3 | United Kingdom | ||
| 23 | EUCTR2019-004167-45-FI (EUCTR) | 18/05/2020 | 15/04/2020 | A study to test how taking BI 1015550 for 12 weeks affects lungfunction in people with idiopathic pulmonary fibrosis (IPF). | A randomised, double-blind, placebo-controlled parallel groupstudy in IPF patients over 12 weeks evaluating efficacy, safety andtolerability of BI 1015550 taken orally. | Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 Product Code: BI 1015550 INN or Proposed INN: BI 1015550 Other descriptive name: BI 1015550 | Boehringer Ingelheim Finland Ky | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | United States;Czechia;Slovakia;Greece;Finland;Spain;Ukraine;Austria;Russian Federation;Chile;United Kingdom;Italy;Hungary;Mexico;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;Japan;China;Korea, Republic of | ||
| 24 | ChiCTR2000031386 | 2020-04-01 | 2020-03-29 | The impact of NAC treatment in IPF patients in mainland China: a retrospective study | The impact of NAC treatment in IPF patients in mainland China: a retrospective study | idiopathic pulmonary fibrosis | Study group:acetylcysteine 0.6 tid po.;control group:did not take NAC or other antifibrotic drugs; | Shanghai Pulmonary Hospital, Tongji University School of Medicine | NULL | Recruiting | Both | Study group:348;control group:174; | China | |||
| 25 | EUCTR2018-002664-73-GB (EUCTR) | 24/09/2019 | 22/01/2019 | Clinical study of the inhaled research drug TD139 to test its effectiveness and safety in patients with a serious scarring disease of the lung over 52 weeks. | GALACTIC-1- A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks | patients with idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10067761;Term: Exacerbation of idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Product Name: TD139 Product Code: TD139 INN or Proposed INN: TD139 Other descriptive name: DEX284 Product Name: TD139 Product Code: TD139 INN or Proposed INN: TD139 Other descriptive name: DEX284 | Galecto Biotech AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2 | United States;France;Canada;Spain;Poland;Belgium;Ireland;Israel;Germany;Italy;United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT04030026 (ClinicalTrials.gov) | August 8, 2019 | 11/7/2019 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough | Nalbuphine;Idiopathic Pulmonary Fibrosis;Cough | Drug: Nalbuphine ER;Drug: Placebo oral tablet | Trevi Therapeutics | Parexel | Recruiting | 18 Years | 80 Years | All | 60 | Phase 2 | United Kingdom |
| 27 | EUCTR2018-002664-73-PL (EUCTR) | 09/07/2019 | 14/03/2019 | Clinical study of the inhaled research drug TD139 to test its effectiveness and safety in patients with a serious scarring disease of the lung over 52 weeks. | GALACTIC-1- A randomized, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks | patients with idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 20.0;Level: LLT;Classification code 10067761;Term: Exacerbation of idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Product Name: TD139 Product Code: TD139 INN or Proposed INN: TD139 Other descriptive name: DEX284 Product Name: TD139 Product Code: TD139 INN or Proposed INN: TD139 Other descriptive name: DEX284 | Galecto Biotech AB | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 450 | Phase 2 | Israel;Germany;United Kingdom;Italy;United States;France;Canada;Spain;Belgium;Poland;Ireland | ||
| 28 | EUCTR2018-004447-23-DE (EUCTR) | 04/07/2019 | 07/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Netherlands;Germany;United Kingdom;Italy | ||
| 29 | EUCTR2018-004744-31-GB (EUCTR) | 24/06/2019 | 05/03/2019 | Efficacy and Safety Study: Nalbuphine ER Tablets for the Treatment of Cough in Idiopathic Pulmonary Fibrosis | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis With Nalbuphine ER Tablets for the Treatment of Cough - CANAL | Treatment of Cough in Idiopathic Pulmonary Fibrosis;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Product Name: Nalbuphine Extended-Realease (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE Product Name: Nalbuphine Extended-Release (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE Product Name: Nalbuphine Extended-Release (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE Product Name: Nalbuphine Extended-Release (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE | Trevi Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | United Kingdom | ||
| 30 | EUCTR2018-004447-23-IT (EUCTR) | 18/06/2019 | 10/11/2020 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: cromolyn sodio (cromoglicato disodico, DSCG) Product Code: [RVT-1601 (in precedenza PA101B)] INN or Proposed INN: cromoglicato disodico Other descriptive name: SODIUM CROMOGLICATE Product Name: cromolyn sodio (cromoglicato disodico, DSCG) Product Code: [RVT-1601 (in precedenza PA101B)] INN or Proposed INN: cromoglicato disodico Other descriptive name: SODIUM CROMOGLICATE Product Name: cromolyn sodio (cromoglicato disodico, DSCG) Product Code: [RVT-1601 (in precedenza PA101B)] INN or Proposed INN: cromoglicato disodico Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences, GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czechia;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | EUCTR2018-001405-87-BE (EUCTR) | 27/05/2019 | 28/11/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Brazil;Australia;Denmark;Peru;Germany | ||
| 32 | EUCTR2018-004447-23-GB (EUCTR) | 20/05/2019 | 15/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial RESPIVANT RVT1601-cc-04 | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;New Zealand;Italy;United Kingdom | ||
| 33 | EUCTR2018-004447-23-CZ (EUCTR) | 15/05/2019 | 14/03/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| 34 | EUCTR2018-004447-23-BE (EUCTR) | 02/05/2019 | 01/04/2019 | Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) | Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial - SCENIC Trial | Persistent cough in Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: LLT;Classification code 10070801;Term: Persistent cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE Product Name: Cromolyn sodium [Disodium Cromoglycate] Product Code: RVT-1601 (formerly, PA101B) INN or Proposed INN: SODIUM CROMOGLICATE Other descriptive name: SODIUM CROMOGLICATE | Respivant Sciences GmbH | NULL | Not Recruiting | Female: yes Male: yes | 180 | Phase 2 | United States;Czech Republic;Canada;Belgium;Turkey;Australia;Netherlands;Germany;United Kingdom;New Zealand;Italy | ||
| 35 | EUCTR2018-001405-87-GB (EUCTR) | 29/03/2019 | 05/12/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Czechia;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Brazil;Australia;Denmark;Peru;Germany | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2018-001405-87-DE (EUCTR) | 21/03/2019 | 26/11/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Brazil;Australia;Denmark;Peru;Germany | ||
| 37 | EUCTR2017-004302-18-FI (EUCTR) | 05/03/2019 | 04/09/2018 | A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1205 Product Code: G321605 INN or Proposed INN: NA Other descriptive name: GLPG1205 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;Egypt;Slovakia;Finland;Ukraine;Oman;Romania;Croatia;Bulgaria;Sweden | ||
| 38 | EUCTR2018-001405-87-GR (EUCTR) | 21/02/2019 | 22/01/2019 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Brazil;Australia;Denmark;Peru;Germany | ||
| 39 | EUCTR2018-001405-87-CZ (EUCTR) | 23/01/2019 | 06/12/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Brazil;Australia;Denmark;Peru;Germany | ||
| 40 | EUCTR2018-001406-29-HU (EUCTR) | 17/01/2019 | 04/12/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Israel;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;South Africa;Netherlands;Germany;New Zealand;Japan;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | EUCTR2017-004302-18-HR (EUCTR) | 14/01/2019 | 16/05/2019 | A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1205 Product Code: G321605 INN or Proposed INN: NA Other descriptive name: GLPG1205 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;Egypt;Slovakia;Finland;Ukraine;Oman;Romania;Croatia;Bulgaria;Sweden | ||
| 42 | EUCTR2018-001406-29-PL (EUCTR) | 21/12/2018 | 17/12/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Israel;Italy;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;South Africa;Germany;Netherlands;New Zealand;Japan;Korea, Republic of | ||
| 43 | EUCTR2018-001405-87-DK (EUCTR) | 20/12/2018 | 22/11/2018 | A clinical study to test how effective and safe GLPG1690 is for subjects with idiopathic pulmonary fibrosis (IPF) when used together with standard medical treatment | A Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multi-center study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. | Idiopatic pulmonary fibrosis MedDRA version: 20.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 Product Name: GLPG1690 Product Code: G451990 INN or Proposed INN: ziritaxestat Other descriptive name: GLPG1690 | Galapagos NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Taiwan;Greece;Finland;Spain;Turkey;Chile;United Kingdom;Czech Republic;Belgium;Brazil;Denmark;Australia;Peru;Germany | ||
| 44 | EUCTR2017-004302-18-SE (EUCTR) | 03/12/2018 | 01/08/2018 | A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1205 Product Code: G321605 INN or Proposed INN: NA Other descriptive name: GLPG1205 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;Egypt;Slovakia;Finland;Ukraine;Oman;Romania;Croatia;Bulgaria;Sweden | ||
| 45 | EUCTR2017-004919-39-DE (EUCTR) | 20/11/2018 | 16/07/2018 | A study to test the safety, tolerability, biological activity, and pharmacokinetics of the drug ND-L02-s0201 compared with a placebo in patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: ND-L02-s0201 for injection INN or Proposed INN: TBC | Nitto Denko Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 2 | United States;Germany;United Kingdom;Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | EUCTR2017-003158-18-DK (EUCTR) | 15/11/2018 | 16/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Australia;Netherlands;Germany;Korea, Republic of | ||
| 47 | EUCTR2017-004302-18-BG (EUCTR) | 22/10/2018 | 06/08/2018 | A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1205 Product Code: G321605 INN or Proposed INN: NA Other descriptive name: GLPG1205 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;Egypt;Slovakia;Finland;Ukraine;Oman;Romania;Croatia;Bulgaria;Sweden | ||
| 48 | EUCTR2017-003158-18-NL (EUCTR) | 10/10/2018 | 24/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - SPIRIT | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 49 | EUCTR2017-003158-18-GR (EUCTR) | 21/09/2018 | 25/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 50 | EUCTR2017-003158-18-CZ (EUCTR) | 12/09/2018 | 09/05/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT03286556 (ClinicalTrials.gov) | September 4, 2018 | 12/9/2017 | Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis | Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF) | Idiopathic Pulmonary Fibrosis, Acute Fatal Form | Drug: Autoantibody Reductive Therapy;Drug: Treatment as Usual (TAU) | University of Alabama at Birmingham | National Heart, Lung, and Blood Institute (NHLBI);Brigham and Women's Hospital;Temple University;University of Pittsburgh | Recruiting | 40 Years | 85 Years | All | 51 | Phase 2 | United States |
| 52 | EUCTR2017-003158-18-IT (EUCTR) | 03/09/2018 | 05/11/2020 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis - Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: NA Product Name: humanized anti-alpha v beta 6 mAb Product Code: [BG00011] INN or Proposed INN: Not yet assigned | BIOGEN IDEC RESEARCH LIMITED | NULL | Not Recruiting | Female: yes Male: yes | 290 | Phase 2 | United States;Czechia;Greece;Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;France;Czech Republic;Canada;Argentina;Poland;Belgium;Denmark;Germany;Netherlands;Korea, Republic of | ||
| 53 | NCT03535545 (ClinicalTrials.gov) | August 1, 2018 | 11/5/2018 | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis Patients | Pulmonary Fibrosis;Lung Cancer | Drug: [68Ga]CBP8;Diagnostic Test: PET Imaging | Massachusetts General Hospital | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 18 Years | 80 Years | All | 25 | Phase 1 | United States |
| 54 | EUCTR2017-003158-18-ES (EUCTR) | 27/07/2018 | 05/06/2018 | Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosis | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis | mild to moderate Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: humanized anti-alpha v beta 6 mAb Product Code: BG00011 INN or Proposed INN: Not yet assigned Other descriptive name: BG00011 | Biogen Idec Research Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 290 | Phase 2 | United States;Greece;Spain;Turkey;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Canada;Argentina;Poland;Belgium;Australia;Denmark;Netherlands;Germany;Korea, Republic of | ||
| 55 | NCT03928847 (ClinicalTrials.gov) | July 1, 2018 | 18/4/2019 | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis. | Idiopathic Pulmonary Fibrosis | Drug: Epigallocatechin-3-gallate (EGCG) | University of California, San Francisco | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 40 Years | 70 Years | All | 35 | Early Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | EUCTR2017-004302-18-SK (EUCTR) | 18/06/2018 | 04/05/2018 | A clinical study to test how effective and safe GLPG1205 is for patients with Idiopathic Pulmonary Fibrosis (IPF) | A Phase II randomized, double-blind, placebo-controlled, 26-week study to evaluate the efficacy, safety and tolerability of GLPG1205 in subjects with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: GLPG1205 Product Code: G321605 INN or Proposed INN: NA Other descriptive name: GLPG1205 | Galapagos NV | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 2 | France;Egypt;Slovakia;Finland;Ukraine;Oman;Romania;Croatia;Bulgaria;Sweden | ||
| 57 | EUCTR2017-002667-17-DE (EUCTR) | 04/06/2018 | 23/01/2018 | Study of pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VAY736 INN or Proposed INN: not established Other descriptive name: VAY736 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 58 | Phase 2 | United States;France;Canada;Ireland;Germany;United Kingdom;Italy | ||
| 58 | EUCTR2016-003827-45-GR (EUCTR) | 29/05/2018 | 16/05/2018 | AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE | AN OPEN LABEL PHASE IV, MULTICENTER, INTERNATIONAL, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT OF DIET ON GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH IPF TREATED WITH PIRFENIDONE - MADIET | Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: ESBRIET Product Name: ESBRIET INN or Proposed INN: PIRFENIDONE Other descriptive name: ESBRIET Trade Name: ESBRIET Product Name: ESBRIET INN or Proposed INN: PIRFENIDONE Other descriptive name: ESBRIET Trade Name: ESBRIET Product Name: ESBRIET INN or Proposed INN: PIRFENIDONE Other descriptive name: ESBRIET | CIBERES - Instituto Carlos III | Institut d'Investigació Biomédica de Bellvitge (IDIBELL) | Not Recruiting | Female: yes Male: yes | 90 | Phase 4 | Greece;Spain;United Kingdom | ||
| 59 | EUCTR2017-002667-17-GB (EUCTR) | 18/05/2018 | 08/11/2017 | Study of pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VAY736 INN or Proposed INN: not established Other descriptive name: VAY736 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 58 | Phase 2 | United States;France;Canada;Ireland;Germany;Italy;United Kingdom | ||
| 60 | EUCTR2017-002667-17-IE (EUCTR) | 06/04/2018 | 08/11/2017 | Study of pharmacodynamics, pharmacokinetics, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: VAY736 INN or Proposed INN: not established Other descriptive name: VAY736 | Novartis Pharma AG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 58 | Phase 2 | United States;France;Canada;Ireland;Germany;United Kingdom;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | EUCTR2015-002619-14-FR (EUCTR) | 21/06/2017 | 25/04/2018 | Efficacy and safety of nintedanib co-administered with sildenafil in IPF patients with advanced lung function impairment | A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment | patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Revatio Product Name: Revatio 20 mg Product Code: sildenafil INN or Proposed INN: SILDENAFIL Other descriptive name: sildenafil | Boehringer Ingelheim France | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Spain;Italy;United Kingdom;India;France;Mexico;Canada;Belgium;Australia;Germany;China;Japan;Korea, Republic of | ||
| 62 | JPRN-jRCTs071180049 | 23/05/2017 | 15/03/2019 | Japanese Intergroup Study of Nintedanib for NSCLC with IPF | A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - J-SONIC | Advanced Non-small cell lung cancer with idiopathic pulmonary fibrosis | carboplatin + nab-paclitaxel carboplatin + nab-paclitaxel + nintedanib | Okamoto Isamu | Otsubo Kohei | Not Recruiting | >= 20age old | Not applicable | Both | 240 | Phase 3 | Japan |
| 63 | JPRN-UMIN000026799 | 2017/05/12 | 01/04/2017 | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis | A randomized phse 3 study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis - Japanese Intergroup Study of Nintedanib for NSCLC with IPF (J-SONIC) | Non-small-cell lung cancer with idiopathic pulmonary fibrosis | A: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) repeated every 3 weeks B: 4 cycles of Carboplatin (AUC 6, day 1) plus nab-Paclitaxel (100 mg/m2, day 1, 8, 15) in combination with nintedanib (150 mg B.I.D, daily) repeated every 3 weeks followed by single-agent administration of nintedanib (150 mg B.I.D, daily) | Research Institute for Diseases of the Chest, Kyushu University | NULL | Complete: follow-up continuing | 20years-old | Not applicable | Male and Female | 240 | Phase 3 | Japan |
| 64 | EUCTR2015-005131-40-CZ (EUCTR) | 20/03/2017 | 16/12/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Germany;Netherlands | ||
| 65 | EUCTR2015-005131-40-HU (EUCTR) | 16/01/2017 | 01/12/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Hungary;Czech Republic;Canada;Belgium;South Africa;Netherlands;Germany | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2015-005131-40-BE (EUCTR) | 16/12/2016 | 20/10/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Germany;Netherlands | ||
| 67 | EUCTR2015-005131-40-DE (EUCTR) | 08/12/2016 | 25/10/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Addedto Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis andRisk of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLEDSTUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTSWITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 21.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Germany;Netherlands | ||
| 68 | EUCTR2015-005131-40-GR (EUCTR) | 06/12/2016 | 03/11/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Netherlands;Germany | ||
| 69 | EUCTR2015-005131-40-NL (EUCTR) | 02/12/2016 | 13/10/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Risk of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND RISK OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Netherlands;Germany | ||
| 70 | EUCTR2015-003148-38-PL (EUCTR) | 08/11/2016 | 04/10/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Poland;Belgium;Australia;Germany;Japan;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | EUCTR2015-005131-40-ES (EUCTR) | 20/10/2016 | 09/09/2016 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Intermediate or High Probability of Pulmonary Hypertension due to the lung disease. | A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATHIC PULMONARY FIBROSIS AND INTERMEDIATE OR HIGH PROBABILITY OF GROUP 3 PULMONARY HYPERTENSION. | Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Sildenafil Product Name: Sildenafil Product Code: RO0280296 INN or Proposed INN: SILDENAFIL | F. Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 176 | Phase 2 | United Arab Emirates;Greece;Spain;Turkey;Israel;Italy;Egypt;Czech Republic;Hungary;Canada;Belgium;South Africa;Germany;Netherlands | ||
| 72 | EUCTR2015-002619-14-BE (EUCTR) | 25/07/2016 | 03/06/2016 | Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairment | INSTAGE (TM) : A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment - INSTAGE (TM) | patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Revatio Product Name: Revatio 20 mg Product Code: sildenafil INN or Proposed INN: SILDENAFIL Other descriptive name: sildenafil | SCS Boehringer Ingelheim Comm. V | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Spain;United Kingdom;Italy;India;France;Mexico;Canada;Belgium;Australia;Germany;China;Japan;Korea, Republic of | ||
| 73 | EUCTR2015-002619-14-DE (EUCTR) | 21/07/2016 | 04/05/2016 | Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairment | INSTAGE(TM): A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment - INSTAGE(TM) | patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Revatio Product Name: Revatio 20 mg Product Code: sildenafil INN or Proposed INN: SILDENAFIL Other descriptive name: sildenafil | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Spain;United Kingdom;Italy;India;France;Mexico;Canada;Belgium;Australia;Germany;China;Japan;Korea, Republic of | ||
| 74 | EUCTR2015-002619-14-ES (EUCTR) | 29/06/2016 | 17/05/2016 | Efficacy and safety of nintedanib when co-administered with sildenafil in IPF patients with advanced lung function impairment | A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib coadministrated with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment | patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Revatio Product Name: Revatio 20 mg Product Code: sildenafil INN or Proposed INN: SILDENAFIL Other descriptive name: sildenafil | Boehringer Ingelheim España, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 3 | United States;Spain;United Kingdom;Italy;India;France;Mexico;Canada;Belgium;Australia;Germany;China;Japan;Korea, Republic of | ||
| 75 | EUCTR2015-003148-38-ES (EUCTR) | 13/06/2016 | 11/03/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | Boehringer Ingelheim España, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | EUCTR2015-003148-38-BE (EUCTR) | 06/06/2016 | 19/04/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | SCS Boehringer Ingelheim Comm. V | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | ||
| 77 | EUCTR2015-003148-38-HU (EUCTR) | 27/05/2016 | 12/04/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Hungary;Czech Republic;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | ||
| 78 | EUCTR2015-003148-38-CZ (EUCTR) | 26/05/2016 | 11/04/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of;United States | ||
| 79 | EUCTR2015-003148-38-FR (EUCTR) | 24/05/2016 | 04/05/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | Boehringer Ingelheim France | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | ||
| 80 | EUCTR2015-003148-38-FI (EUCTR) | 17/05/2016 | 12/04/2016 | Effect of nintedanib on biomarkers | A 12-week, double blind, randomised, placebo controlled, parallel group trial followed by a single active arm phase of 40 weeks evaluating the effect of oral nintedanib 150 mg twice daily on change in biomarkers of extracellular matrix (ECM) turnover in patients with idiopathic pulmonary fibrosis (IPF) and limited forced vital capacity (FVC) impairment. | MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB | Boehringer Ingelheim Finland Ky | NULL | Not Recruiting | Female: yes Male: yes | 490 | Phase 4 | United States;Finland;Spain;United Kingdom;France;Czech Republic;Hungary;Belgium;Poland;Australia;Germany;Japan;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | JPRN-JapicCTI-163326 | 01/5/2016 | 22/07/2016 | Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis | Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) | Intervention name : ART-123 INN of the intervention : thrombomodulin alfa Dosage And administration of the intervention : 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy Control intervention name : Placebo Dosage And administration of the control intervention : Placebo by intravenous drip infusion in addition to standard of care steroid therapy | ASAHI KASEI PHARMA CORPORATION | NULL | recruiting | 40 | 85 | BOTH | Phase 3 | NULL | |
| 82 | EUCTR2015-003280-11-NL (EUCTR) | 29/04/2016 | 19/01/2016 | A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary Fibrosis | AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 4 | France;United States;Canada;Spain;Denmark;Germany;Netherlands;Italy | ||
| 83 | EUCTR2015-003280-11-DE (EUCTR) | 25/02/2016 | 19/10/2015 | A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary Fibrosis | AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 4 | France;United States;Canada;Spain;Denmark;Netherlands;Germany;Italy | ||
| 84 | EUCTR2014-005658-20-BG (EUCTR) | 23/02/2016 | 18/12/2015 | FG-3019 treatment in Idiopathic Pulmonary Fibrosis (IPF) patients. | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 19.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 19.1;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;Level: HLT;Classification code 10033979;Term: Parenchymal lung disorders NEC;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: FG-3019 10mg/mL in 10 mL vials Product Code: FG-3019 INN or Proposed INN: Pamrevlumab | FibroGen, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 136 | Phase 2 | United States;Canada;Australia;South Africa;Bulgaria;New Zealand;India | ||
| 85 | JPRN-UMIN000020682 | 2016/01/22 | 22/01/2016 | The comparison of the efficacy and safety of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis | Idiopathic pulmonary fibrosis | pirfenidone 12 months 200-600mg t.i.d or b.i.d nintedanib 12 months 100-150mg b.i.d | National Hospital Organization Ibarakihigashi National HospitalThe center of Chest Diseases and Severe Motor&Intellectual Disabilities | NULL | Pending | 20years-old | Not applicable | Male and Female | 60 | Not applicable | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | EUCTR2015-003280-11-DK (EUCTR) | 20/01/2016 | 25/11/2015 | A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary Fibrosis | AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 4 | France;United States;Canada;Spain;Denmark;Netherlands;Germany;Italy | ||
| 87 | EUCTR2015-000640-42-IT (EUCTR) | 22/12/2015 | 22/02/2018 | Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib incombination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - - | Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev INN or Proposed INN: nintedanib Other descriptive name: nintedanib Trade Name: Ofev INN or Proposed INN: Nintedanib Other descriptive name: NINTEDANIB Trade Name: Esbriet INN or Proposed INN: PIRFENIDONE Other descriptive name: PIRFENIDONE | BOEHRINGER-INGELHEIM ITALIA S.P.A. | NULL | Not Recruiting | Female: yes Male: yes | 135 | Phase 4 | France;United States;Canada;Netherlands;Germany;Italy | ||
| 88 | EUCTR2015-003280-11-ES (EUCTR) | 16/12/2015 | 30/10/2015 | A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary Fibrosis | AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Esbriet Product Code: RO0220912 INN or Proposed INN: PIRFENIDONE Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB Trade Name: Ofev Product Name: Ofev Product Code: 534-1508 INN or Proposed INN: NINTEDANIB | Roche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 4 | France;United States;Canada;Spain;Denmark;Netherlands;Germany;Italy | ||
| 89 | EUCTR2015-000640-42-DE (EUCTR) | 01/12/2015 | 03/09/2015 | Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability and PK of nintedanib iin combination with pirfenidone in IPF | Idiopathic Pulmonary Fibrosis MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Esbriet Product Name: pirfenidone Product Code: pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: PIRFENIDONE | Boehringer Ingelheim Pharma GmbH & Co.KG | NULL | Not Recruiting | Female: yes Male: yes | 135 | Phase 4 | France;United States;Canada;Netherlands;Germany;Italy | ||
| 90 | EUCTR2014-000861-32-DE (EUCTR) | 01/12/2015 | 02/09/2015 | Standard-armed controlled study to assess the impact of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) | Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)A randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial - RELIEF | 1.Fibrotic NSIP., 2.Chronic Hypersensitivity Pneumonitis 3. Lung fibrosis associated with collagen / vascular diseases, 4.Asbestos-induced lung fibrosis MedDRA version: 20.0;Level: LLT;Classification code 10022612;Term: Interstitial lung fibrosis;System Organ Class: 100000004855 MedDRA version: 20.0;Classification code 10035754;Term: Pneumonitis hypersensitivity;Classification code 10025088;Term: Lung fibrosis;Classification code 10022617;Term: Interstitial pneumonia;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet® (Pirfenidon) Product Name: Esbriet® (Pirfenidon) Product Code: PZN 8881655(RochePharma AG) INN or Proposed INN: PIRFENIDONE | Justus Liebig Universität Giessen | NULL | Not Recruiting | Female: yes Male: yes | 374 | Phase 2 | Germany | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | EUCTR2015-000492-27-FR (EUCTR) | 24/11/2015 | 11/09/2015 | N/A | N/A - EXAFIP | MedDRA version: 18.0;Level: LLT;Classification code 10067761;Term: Exacerbation of idiopathic pulmonary fibrosis;System Organ Class: 100000004855 | Trade Name: ENDOXAN Product Name: ENDOXAN INN or Proposed INN: Cyclosphamine Other descriptive name: ENDOXAN Trade Name: UROMITEXAN Product Name: UROMITEXAN INN or Proposed INN: MESNA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 3 | France | ||
| 92 | EUCTR2015-000640-42-NL (EUCTR) | 13/10/2015 | 18/08/2015 | Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability and PK of nintedanib iin combination with pirfenidone in IPF | Idiopathic Pulmonary Fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Esbriet Product Name: pirfenidone Product Code: pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: PIRFENIDONE | Boehringer Ingelheim bv | NULL | Not Recruiting | Female: yes Male: yes | 135 | Phase 4 | France;United States;Canada;Germany;Netherlands;Italy | ||
| 93 | NCT01462006 (ClinicalTrials.gov) | October 2015 | 26/10/2011 | Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF) | Double-blind Placebo-controlled Pilot Study of Sirolimus in IPF | Idiopathic Pulmonary Fibrosis;Diffuse Parenchymal Lung Disease;Interstitial Lung Disease | Drug: sirolimus;Other: Placebo | University of Virginia | National Heart, Lung, and Blood Institute (NHLBI) | Unknown status | 21 Years | 85 Years | All | 32 | N/A | United States |
| 94 | EUCTR2015-000640-42-FR (EUCTR) | 26/08/2015 | 05/08/2015 | Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPF | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Ofev Product Name: Ofev 100 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Ofev Product Name: Ofev 150 mg capsule Product Code: nintedanib INN or Proposed INN: nintedanib Other descriptive name: NINTEDANIB Trade Name: Esbriet Product Name: pirfenidone Product Code: pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: PIRFENIDONE | Boehringer Ingelheim France | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 135 | United States;France;Canada;Netherlands;Germany;Italy | |||
| 95 | EUCTR2014-003933-24-ES (EUCTR) | 30/04/2015 | 03/03/2015 | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study | Idiopathic pulmonary fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: SAR156597 INN or Proposed INN: NA | sanofi-aventis recherche & développement | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Denmark;Germany;Korea, Republic of;Portugal;United States;Greece;Spain;Turkey;Israel;Chile;Colombia;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | EUCTR2014-003933-24-DK (EUCTR) | 07/04/2015 | 20/02/2015 | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis | Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study - ESTAIR | Idiopathic pulmonary fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: SAR156597 Product Code: SAR156597 INN or Proposed INN: SAR156597 | sanofi-aventis recherche & développement | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;United States;Greece;Spain;Turkey;Israel;Chile;Colombia;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Denmark;Australia;Germany;Korea, Republic of | ||
| 97 | JPRN-UMIN000016826 | 2015/03/31 | 31/03/2015 | The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. | The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. - The evaluation of oxidative stress and the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis (IPF) | Pirfenidone Observation | National Hospital Organization Ibarakihigashi National Hospital | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 40 | Not applicable | Japan |
| 98 | EUCTR2014-004025-40-NL (EUCTR) | 06/02/2015 | 11/12/2014 | Treatment of chronic cough with PA101. | Treatment of Chronic Idiopathic Cough (CIC) and Chronic Cough in patients with Idiopathic Pulmonary Fibrosis (IPF) with PA101. - Treatment of chronic cough with PA101 | Chronic Idiopathic Cough and Chronic Cough in Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: LLT;Classification code 10066656;Term: Chronic cough;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Disodium Cromoglycate [cromolyn sodium] Product Code: PA101 INN or Proposed INN: Not available Other descriptive name: Disodium cromoglycate (DSCG) | Patara Pharma | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Netherlands;United Kingdom | |||
| 99 | JPRN-UMIN000015508 | 2015/01/01 | 24/10/2014 | A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | A prospective randomized, multicenter trial evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis | Using Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks. Pirfenidone 1200-1800mg (control group) | Grant for Research on Diffuse Lung Disease from the Ministry of Health, Labour and Welfare of Japan. | NULL | Complete: follow-up complete | 40years-old | Not applicable | Male and Female | 150 | Not selected | Japan |
| 100 | EUCTR2014-004058-32-GB (EUCTR) | 19/12/2014 | 12/06/2015 | Treating pulmonary fibrosis with co-trimoxazole | The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary Fibrosis with the Addition of Co-trimoxazole (EME-TIPAC) - Treating pulmonary fibrosis with co-trimoxazole | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Cotrimoxazole Product Name: Cotrimoxazole Product Code: NA INN or Proposed INN: trimethoprim Other descriptive name: none INN or Proposed INN: sulphamethoxazole Other descriptive name: none | Norfolk and Norwich University Hospital NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 330 | Phase 3 | United Kingdom | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | JPRN-JapicCTI-142708 | 24/10/2014 | 14/11/2014 | A phase II study of Lebrikizumab | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY | IDIOPATHIC PULMONARY FIBROSIS | Intervention name : RO5490255 INN of the intervention : Lebrikizumab Dosage And administration of the intervention : 250mg SC injection every 4 weeks Control intervention name : Placebo Dosage And administration of the control intervention : SC injection every 4 weeks | Chugai Pharmaceutical Co., Ltd. | NULL | 40 | BOTH | 480 | Phase 2 | NULL | ||
| 102 | EUCTR2014-000963-42-DE (EUCTR) | 01/10/2014 | 13/08/2014 | A phase II study to assess vismodegib in the treatment of idiopathic pulmonary fibrosis | A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of oral vismodegib for the treatment of idiopathic pulmonary fibrosis - ISLAND | Idiopathic pulmonary fibrosis MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Erivedge INN or Proposed INN: vismodegib Other descriptive name: VISMODEGIB | F. Hoffmann-La Roche Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | United States;France;Mexico;Spain;Peru;Australia;Israel;Chile;Germany;New Zealand;Italy;Korea, Republic of | ||
| 103 | EUCTR2014-003423-21-BE (EUCTR) | 29/09/2014 | 29/08/2014 | Evaluation of impact of inhaled nitric oxide on pulmonary vessel blood volume measured by high resolution computed tomography (HRCT) in subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in subjects with WHO Group 3 Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) on Long-Term Oxygen Therapy (LTOT) (Part 2). | An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects with WHO Group 3 PH associated with Idiopathic pulmonary fibrosis (IPF) on LTOT (Part 2). | Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF) MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1;Level: LLT;Classification code 10010952;Term: COPD;Classification code 10009033;Term: Chronic obstructive pulmonary disease;Classification code 10037400;Term: Pulmonary hypertension;Level: HLT;Classification code 10037401;Term: Pulmonary hypertensions;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: INOmax 400ppm mol/mol inhalation gas Product Name: INO INN or Proposed INN: NITRIC OXIDE | Bellerophon Pulse Technologies LLC | NULL | Not Recruiting | Female: yes Male: yes | Phase 1;Phase 2 | Belgium | |||
| 104 | EUCTR2013-004404-19-GB (EUCTR) | 07/05/2014 | 25/03/2014 | Effect of Fostair® on biomarkers of platelet adhesion in Idiopathic pulmonary fibrosis | A Randomized, Double-blind, Placebo-controlled, Crossover Study toAssess the Effect of 28 Day Treatment with Fostair® pMDI 200/12 on biomarkers of platelet adhesion in Patients with Idiopathic pulmonary fibrosis. - Effect of Fostair® pMDI on biomarkers of platelet adhesion in IPF | Idiopathic pulmonary fibrosis MedDRA version: 16.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fostair INN or Proposed INN: beclometasone dipropionate INN or Proposed INN: formoterol fumarate dihydrate | Hull and East Yorkshire Hospitals NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 105 | EUCTR2013-001163-24-BE (EUCTR) | 28/04/2014 | 10/02/2014 | A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | IDIOPATHIC PULMONARY FIBROSIS;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: lebrikizumab Product Code: RO5490255/F01-02 INN or Proposed INN: LEBRIKIZUMAB Other descriptive name: TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A Trade Name: ESBRIET INN or Proposed INN: PIRFENIDONE | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 480 | Phase 2 | United States;Spain;United Kingdom;Italy;France;Mexico;Canada;Belgium;Poland;Australia;Peru;Germany;Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | NCT02055456 (ClinicalTrials.gov) | February 2014 | 3/2/2014 | Nandrolone Decanoate in the Treatment of Telomeropathies | Male Hormones for Telomere Related Diseases | Aplastic Anemia;Bone Marrow Failure Syndromes;Idiopathic Pulmonary Fibrosis;Telomere Shortening | Drug: Nandrolone Decanoate | University of Sao Paulo | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Recruiting | 2 Years | N/A | Both | 20 | Phase 1;Phase 2 | Brazil |
| 107 | NCT01969409 (ClinicalTrials.gov) | January 2014 | 17/10/2013 | Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis | Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF) | Ambulatory IPF | Drug: Rituximab;Drug: Placebo | University of Alabama at Birmingham | National Institutes of Health (NIH) | Active, not recruiting | 50 Years | 85 Years | All | 58 | Phase 2 | United States |
| 108 | EUCTR2013-001163-24-IT (EUCTR) | 19/11/2013 | 05/09/2013 | A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | IDIOPATHIC PULMONARY FIBROSIS;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: lebrikizumab Product Code: RO5490255/F01-02 INN or Proposed INN: LEBRIKIZUMAB Other descriptive name: TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | F. Hoffmann-La Roche Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 250 | Phase 2 | France;United States;Mexico;Canada;Spain;Poland;Australia;Peru;Germany;Japan;United Kingdom;Italy | ||
| 109 | EUCTR2013-001163-24-PL (EUCTR) | 09/11/2013 | 01/10/2013 | A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | IDIOPATHIC PULMONARY FIBROSIS;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: lebrikizumab Product Code: RO5490255/F01-02 INN or Proposed INN: LEBRIKIZUMAB Other descriptive name: TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A Trade Name: ESBRIET INN or Proposed INN: PIRFENIDONE | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 480 | Phase 2 | United States;Spain;United Kingdom;Italy;France;Mexico;Canada;Poland;Belgium;Australia;Peru;Germany;Japan | ||
| 110 | EUCTR2013-001163-24-DE (EUCTR) | 04/11/2013 | 28/08/2013 | A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | IDIOPATHIC PULMONARY FIBROSIS;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: lebrikizumab Product Code: RO5490255/F01-02 INN or Proposed INN: LEBRIKIZUMAB Other descriptive name: TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A Trade Name: ESBRIET INN or Proposed INN: PIRFENIDONE | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 480 | Phase 2 | United States;Spain;United Kingdom;Italy;France;Mexico;Canada;Belgium;Poland;Australia;Peru;Germany;Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | JPRN-UMIN000021109 | 2013/10/21 | 19/02/2016 | Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer | Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer - Preventive effect of Sivelestat Na Hydrate on postoperative acute exacerbation of idiopathic interstitial pneumonia in the patient with lung cancer (Sivelestat trial) | idiopathic interstitial pneumonia (IIP) | Control (n=30): intra- and postoperative management without Sivelestat Trial (n=30): 7days administration of Sivelestat 0.2microgram/kgBW/hr div started from surgical operation | Japanese Northern East Area Thoracic Surgery Study Group (JNETS) | NULL | Complete: follow-up complete | 25years-old | 80years-old | Male and Female | 120 | Phase 3 | Japan |
| 112 | EUCTR2013-003301-26-GB (EUCTR) | 20/09/2013 | 04/11/2013 | A clinical trial to assess whether a treatment reducing acid production in the stomach (omeprazole) can reduce cough in patients with scarring of the lungs. | A randomised placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis (IPF) - Pilot trial of omeprazole in idiopathic pulmonary fibrosis (Acronym : | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Omeprazole (UK licensed generic product) Product Name: Omeprazole INN or Proposed INN: Omeprazole | Newcastle Upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | United Kingdom | |||
| 113 | EUCTR2013-001163-24-ES (EUCTR) | 20/09/2013 | 16/09/2013 | A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | IDIOPATHIC PULMONARY FIBROSIS;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: lebrikizumab Product Code: RO5490255/F01-02 INN or Proposed INN: LEBRIKIZUMAB Other descriptive name: TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 250 | Phase 2 | United States;Spain;United Kingdom;Italy;France;Mexico;Canada;Poland;Belgium;Peru;Australia;Germany;Japan | ||
| 114 | EUCTR2013-001163-24-FR (EUCTR) | 17/09/2013 | 28/09/2015 | A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. | A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS. | IDIOPATHIC PULMONARY FIBROSIS;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: lebrikizumab Product Code: RO5490255/F01-02 INN or Proposed INN: LEBRIKIZUMAB Other descriptive name: TNX-650, rhuMAb anti-IL13, aIL-13, MILR1444A | F. Hoffmann-La Roche Ltd | NULL | Not Recruiting | Female: yes Male: yes | 250 | Phase 2 | United States;Spain;United Kingdom;Italy;France;Mexico;Canada;Poland;Belgium;Australia;Peru;Germany;Japan | ||
| 115 | EUCTR2012-001571-36-PL (EUCTR) | 09/09/2013 | 17/06/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER | Idiopathic pulmonary fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Czech Republic;Canada;Spain;Belgium;Poland;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | EUCTR2012-000564-14-DK (EUCTR) | 28/08/2013 | 12/07/2013 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) | InterMune International AG. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Austria;Denmark;Germany;United Kingdom;Italy;Sweden | ||
| 117 | EUCTR2012-000564-14-AT (EUCTR) | 19/07/2013 | 11/06/2013 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) | InterMune International AG. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden | ||
| 118 | EUCTR2012-000564-14-DE (EUCTR) | 17/07/2013 | 29/05/2013 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) | InterMune International AG. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden | ||
| 119 | EUCTR2012-000564-14-IT (EUCTR) | 17/07/2013 | 07/06/2013 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 16.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) | InterMune International AG. | NULL | Not Recruiting | Female: yes Male: yes | 250 | Phase 2 | Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden | ||
| 120 | EUCTR2012-000564-14-SE (EUCTR) | 25/06/2013 | 24/05/2013 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) | InterMune International AG. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | EUCTR2012-000564-14-BE (EUCTR) | 18/06/2013 | 30/04/2013 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of Pirfenidone - PANORAMA | Patients with Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Fluimucil® 600 mg effervescent tablets INN or Proposed INN: ACETYLCYSTEINE Other descriptive name: N-Acetylcysteine, (NAC) | InterMune International AG. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Denmark;Austria;Germany;United Kingdom;Italy;Sweden | ||
| 122 | EUCTR2012-001571-36-DE (EUCTR) | 17/06/2013 | 02/04/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER). - RAINIER | Idiopathic pulmonary fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of | ||
| 123 | EUCTR2012-001571-36-BE (EUCTR) | 28/05/2013 | 26/03/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER | Idiopathic pulmonary fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | Korea, Democratic People's Republic of;Israel;United Kingdom;Switzerland;Italy;France;Czech Republic;Canada;Belgium;Poland;Australia;Germany;Korea, Republic of;United States;Spain | ||
| 124 | EUCTR2012-001571-36-ES (EUCTR) | 12/05/2013 | 16/05/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINER | Idiopathic pulmonary fibrosis MedDRA version: 16.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Czech Republic;Canada;Poland;Belgium;Spain;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of | ||
| 125 | EUCTR2012-001571-36-CZ (EUCTR) | 29/04/2013 | 15/04/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER). - RAINIER | Idiopathic pulmonary fibrosis MedDRA version: 18.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | EUCTR2012-001571-36-IT (EUCTR) | 26/04/2013 | 28/02/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER | Idiopathic pulmonary fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;United Kingdom;Italy;Korea, Republic of | ||
| 127 | EUCTR2012-001571-36-GB (EUCTR) | 19/04/2013 | 28/03/2013 | A study to evaluate if a new drug is effective in preventing the progression of lung fibrosis | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) - RAINIER | Idiopathic pulmonary fibrosis MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Code: GS-6624 INN or Proposed INN: Simtuzumab Other descriptive name: GS-6624 | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 500 | Phase 2 | United States;Czech Republic;Canada;Poland;Spain;Belgium;Australia;Israel;Germany;Italy;United Kingdom;Korea, Republic of | ||
| 128 | EUCTR2012-005409-38-ES (EUCTR) | 19/04/2013 | 29/01/2013 | First study to test the validity of the treatment of the disease called idiopathic pulmonary fibrosis, which causes inflammation and fibrosis (scarring) of the lung tissue, with a drug called cotrimoxazole. | Pilot study phase III to evaluate the efficacy and safety of Trimethoprim-sulfamethoxazole in the treatment of idiopathic pulmonary fibrosis | Ambulatory patients, men and women, with well-established diagnosis of idiopathic pulmonary fibrosis. MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Parasitic Diseases [C03] | Trade Name: SEPTRIN INN or Proposed INN: TRIMETHOPRIM Other descriptive name: TRIMETHOPRIM INN or Proposed INN: SULFAMETHOXAZOLE | Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI) | NULL | Not Recruiting | Female: yes Male: yes | 56 | Phase 3 | Spain | ||
| 129 | EUCTR2012-005794-31-GB (EUCTR) | 25/03/2013 | 26/02/2013 | A study to assess the effect of a single-does of VRP700 by inhalation to reduce the frequency and severity of cough in adults with Idiopathic Pulmonary Fibrosis (IPF) | A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patients with Idiopathic Pulmonary Fibrosis - EPOCh | Chronic cough in Idiopathic Pulmonary Fibrosis MedDRA version: 16.1;Level: LLT;Classification code 10066656;Term: Chronic cough;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 16.1;Level: PT;Classification code 10011224;Term: Cough;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: VRP700 Product Code: VRP700 | Verona Pharma plc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | United Kingdom | ||||
| 130 | NCT01919827 (ClinicalTrials.gov) | March 2013 | 1/8/2013 | Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis | Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells | Idiopathic Pulmonary Fibrosis | Biological: Endobronchial infusion of adult mesenchymal stem cells;Biological: Autologous mesenchymal stem cells derived from bone marrow | Clinica Universidad de Navarra, Universidad de Navarra | NULL | Completed | 30 Years | 80 Years | All | 17 | Phase 1 | Spain |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 131 | EUCTR2011-002766-21-CZ (EUCTR) | 03/08/2012 | 19/06/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| 132 | EUCTR2011-002766-21-IT (EUCTR) | 25/07/2012 | 19/06/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | BOEHRINGER ING. | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | Portugal;United States;Greece;Finland;Spain;Ireland;Turkey;Russian Federation;Chile;Israel;United Kingdom;Italy;India;Czech Republic;Mexico;Canada;Argentina;Belgium;Brazil;Australia;Germany;China;Japan;Korea, Republic of | ||
| 133 | EUCTR2011-002766-21-DE (EUCTR) | 02/07/2012 | 04/05/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| 134 | EUCTR2011-002766-21-BE (EUCTR) | 26/06/2012 | 26/04/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 17.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | SCS Boehringer Ingelheim Ingelheim Comm.V | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | United States;Portugal;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | |||
| 135 | EUCTR2011-002766-21-ES (EUCTR) | 18/06/2012 | 26/04/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim España S.A | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Chile;Russian Federation;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 136 | EUCTR2011-002766-21-GB (EUCTR) | 15/06/2012 | 21/05/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) - | Idiopathic Pulmonary Fibrosis MedDRA version: 19.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim Limited | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| 137 | EUCTR2011-002766-21-FI (EUCTR) | 06/06/2012 | 16/05/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 17.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| 138 | EUCTR2011-002766-21-GR (EUCTR) | 02/05/2012 | 11/04/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim Hellas | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Chile;Russian Federation;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| 139 | EUCTR2011-002766-21-PT (EUCTR) | 20/04/2012 | 20/04/2012 | Long term safety study of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 20.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Unilfarma - União Internacional de Lab. Farmacêuticos, Lda | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | United States;Portugal;Greece;Spain;Ireland;Russian Federation;Chile;Israel;Italy;India;France;Australia;Netherlands;China;Korea, Republic of;Finland;Turkey;United Kingdom;Czech Republic;Mexico;Canada;Argentina;Brazil;Belgium;Germany;Japan | ||
| 140 | EUCTR2011-003687-78-IT (EUCTR) | 21/02/2012 | 05/03/2012 | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) | Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01 | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | INN or Proposed INN: LANREOTIDE ACETATE Product Name: Gallium68-Dota-Noc Product Code: NA INN or Proposed INN: NA Other descriptive name: NA | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 141 | NCT02136992 (ClinicalTrials.gov) | December 2011 | 11/5/2014 | Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: Pirfenidone;Drug: placebo | Shanghai Pulmonary Hospital, Shanghai, China | Nanjing Chia-tai Tianqing Pharmaceutical | Completed | N/A | 75 Years | Both | 160 | Phase 2 | NULL |
| 142 | EUCTR2010-024211-13-DE (EUCTR) | 20/07/2011 | 12/04/2011 | Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC study | Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC OL | Patients with Idiopathic Pulmonary Fibrosis MedDRA version: 13.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: macitentan | ACTELION Pharmaceuticals Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 178 | Germany;Canada;Turkey;Spain;United States;Sweden;South Africa;Australia;Israel | |||
| 143 | NCT01214187 (ClinicalTrials.gov) | July 2011 | 30/9/2010 | Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis | Phase II Study of Inhaled CO for the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: inhaled carbon monoxide;Other: Oxygen | Brigham and Women's Hospital | National Heart, Lung, and Blood Institute (NHLBI);University of California, San Francisco;University of Chicago;University of Illinois at Chicago;University of Michigan;Columbia University;Tulane University;University of Washington | Completed | 18 Years | 85 Years | All | 58 | Phase 2 | United States |
| 144 | EUCTR2010-024211-13-ES (EUCTR) | 27/06/2011 | 10/11/2011 | Study to evaluate if macitentan is safe and tolerable enough to be usedfor treatment of idiopathic pulmonary fibrosis, following the MUSICstudy | Long term, single-arm, open-label extension study of the MUSIC study toassess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC OL | Patients with Idiopathic Pulmonary Fibrosis MedDRA version: 14.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.0;Level: SOC;Classification code 10038738;Term: Respiratory, thoracic and mediastinal disorders;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: macitentan | ACTELION Pharmaceuticals Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 178 | Germany;Canada;Turkey;Spain;United States;Sweden;South Africa;Australia;Israel | |||
| 145 | EUCTR2010-024252-29-NL (EUCTR) | 16/06/2011 | 11/05/2011 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 485 | Portugal;Greece;Finland;Spain;Germany;Netherlands | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 146 | EUCTR2010-024211-13-SI (EUCTR) | 13/06/2011 | 11/07/2011 | Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC study | Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC OL | Patients with Idiopathic Pulmonary Fibrosis MedDRA version: 14.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: macitentan | ACTELION Pharmaceuticals Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 178 | United States;Slovenia;Canada;Spain;Turkey;Australia;Israel;South Africa;Germany;Sweden | |||
| 147 | EUCTR2010-023828-24-GB (EUCTR) | 09/06/2011 | 27/04/2011 | The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough | The effect of Thalidomide on sputum biomarkers in IPF cough. - The effect of Thalidomide on sputum biomarkers in IPF cough | Cough in Idiopathic Pulmonary fibrosis. | Trade Name: Thalidomide Pharmion Product Name: Thalidomide Pharmion Trade Name: PREDNISOLONE Product Name: prednisolone | University of Nottingham | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 148 | EUCTR2010-024211-13-SE (EUCTR) | 26/05/2011 | 05/04/2011 | Study to evaluate if macitentan is safe and tolerable enough to be used for treatment of idiopathic pulmonary fibrosis, following the MUSIC study | Long term, single-arm, open-label extension study of the MUSIC study to assess the safety and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC OL | Patients with Idiopathic Pulmonary Fibrosis MedDRA version: 13.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: macitentan | ACTELION Pharmaceuticals Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 178 | Germany;Canada;Turkey;Spain;United States;South Africa;Australia;Sweden;Israel | |||
| 149 | EUCTR2010-024252-29-ES (EUCTR) | 25/05/2011 | 03/11/2011 | - | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: BIBF1120 Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: BIBF1120 | Boehringer Ingelheim España, S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 485 | Portugal;Germany;Turkey;Netherlands;Chile;France;Finland;India;Russian Federation;Canada;Mexico;China;Korea, Republic of;Spain;Japan;United States;Greece | |||
| 150 | EUCTR2010-024251-87-BE (EUCTR) | 18/05/2011 | 17/03/2011 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | SCS Boehringer Ingelheim Comm.V | NULL | Not Recruiting | Female: yes Male: yes | 485 | Phase 3 | United States;Ireland;Israel;Italy;United Kingdom;India;France;Czech Republic;Argentina;Belgium;Brazil;Australia;Germany;Japan;China | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 151 | EUCTR2010-024252-29-PT (EUCTR) | 13/05/2011 | 16/02/2011 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim France | NULL | Not Recruiting | Female: yes Male: yes | 485 | China;Japan;Korea, Republic of;United States;Portugal;Greece;Finland;Spain;Russian Federation;India;France;Mexico;Canada;Germany;Netherlands | |||
| 152 | EUCTR2010-024251-87-IE (EUCTR) | 11/05/2011 | 23/03/2011 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Limited | NULL | Not Recruiting | Female: yes Male: yes | 485 | Czech Republic;Belgium;Ireland;Germany;Italy;United Kingdom | |||
| 153 | EUCTR2010-024252-29-GR (EUCTR) | 02/05/2011 | 04/04/2011 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 13.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 485 | Portugal;Greece;Finland;Spain;Netherlands;Germany | |||
| 154 | EUCTR2010-024251-87-GB (EUCTR) | 28/04/2011 | 24/02/2011 | Safety and efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patients | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Limited | NULL | Not Recruiting | Female: yes Male: yes | 485 | Phase 3 | Czech Republic;Belgium;Ireland;Germany;Italy;United Kingdom | ||
| 155 | EUCTR2010-024251-87-CZ (EUCTR) | 26/04/2011 | 08/04/2011 | Safety and Efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patients | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim RCV GmBH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 485 | India;Czech Republic;Argentina;Brazil;Belgium;Australia;Germany;China;Japan;United States;Ireland;Israel;Italy;United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 156 | EUCTR2010-024251-87-DE (EUCTR) | 12/04/2011 | 09/02/2011 | Safety and Efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patients | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on annual Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 485 | United States;Ireland;Israel;Italy;United Kingdom;India;France;Czech Republic;Argentina;Belgium;Brazil;Australia;Germany;Japan;China | |||
| 157 | EUCTR2010-024252-29-DE (EUCTR) | 07/04/2011 | 09/02/2011 | Safety and Efficacy of BIBF 1120 at high dose in Idiopathic Pulmonary Fibrosis patients | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 14.1;Classification code 10037383;Term: Pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 485 | Portugal;United States;Greece;Finland;Spain;Turkey;Russian Federation;Chile;India;France;Mexico;Canada;Netherlands;Germany;Japan;China;Korea, Republic of | |||
| 158 | EUCTR2010-024252-29-FI (EUCTR) | 01/04/2011 | 04/02/2011 | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | A 52 weeks, double blind, randomized, placebo-controlled trial evaluating the effect of oral BIBF 1120, 150 mg twice daily, on Forced Vital Capacity decline , in patients with Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 485 | Portugal;Greece;Finland;Spain;Netherlands;Germany | |||
| 159 | EUCTR2009-011169-98-CZ (EUCTR) | 10/01/2011 | 29/11/2010 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.1;Classification code 10037400;Term: Pulmonary hypertension | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan | Gilead Sciences, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | United Kingdom;Germany;Czech Republic;Italy;Austria | ||
| 160 | EUCTR2009-013788-21-BG (EUCTR) | 05/10/2010 | 18/08/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 16.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim RCV GmBH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 161 | EUCTR2008-004405-34-CZ (EUCTR) | 13/09/2010 | 07/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 162 | EUCTR2009-013788-21-IE (EUCTR) | 05/08/2010 | 20/05/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Ltd | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| 163 | EUCTR2010-020223-44-AT (EUCTR) | 03/08/2010 | 29/06/2010 | (18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia | (18)F-FDG PET/CT in patients with idiopathic interstitial pneumonias: correlation of tracer uptake and histological findings, and texture-based recognition of usual interstitial pneumonia | Interstitial lung disease of unknown etiology | Trade Name: (18)F-FDG Product Name: (18)F-FDG INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE | Medizinische Universität Wien, Univ.Klinik f.Radiodiagnostik | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Austria | ||||
| 164 | EUCTR2009-013788-21-CZ (EUCTR) | 02/08/2010 | 28/07/2010 | study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 19.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: nintedanib | Boehringer Ingelheim RCV GmbH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;Greece;Spain;Ireland;Russian Federation;Italy;United Kingdom;France;Czech Republic;Hungary;Belgium;Bulgaria;Germany | ||
| 165 | EUCTR2008-001281-86-DE (EUCTR) | 02/08/2010 | 16/03/2010 | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: CNTO888 Product Code: CNTO888 | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Germany;Netherlands;Belgium | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 166 | EUCTR2009-013788-21-GR (EUCTR) | 14/07/2010 | 15/11/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Ellas AE | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| 167 | EUCTR2009-013788-21-HU (EUCTR) | 16/06/2010 | 05/07/2010 | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: Nintedanib Other descriptive name: Not applicable Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: Nintedanib Other descriptive name: Not applicable Product Name: BIBF 1120 Product Code: BIBF 1120 INN or Proposed INN: Nintedanib Other descriptive name: Not applicable | Boehringer Ingelheim RCV GmBH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| 168 | EUCTR2009-013788-21-GB (EUCTR) | 04/06/2010 | 11/10/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Limited | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;Italy;United Kingdom | ||
| 169 | EUCTR2009-013788-21-DE (EUCTR) | 27/05/2010 | 22/04/2010 | Roll over study from 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 18.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Pharma GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;Greece;Spain;Ireland;Russian Federation;Chile;United Kingdom;Italy;France;Hungary;Czech Republic;Mexico;Canada;Argentina;Belgium;Brazil;Australia;Bulgaria;Netherlands;Germany;China;Korea, Republic of | ||
| 170 | EUCTR2009-013788-21-PT (EUCTR) | 10/05/2010 | 18/03/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 17.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Unilfarma, Lda. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;Portugal;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 171 | EUCTR2009-013788-21-ES (EUCTR) | 28/04/2010 | 23/02/2010 | Ensayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar IdiopáticaA phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Ensayo clínico de Fase II, abierto, y de extensión para evaluar la tolerabilidad a largo plazo, la seguridad y la eficacia de BIBF 1120 administrado por vía oral en pacientes con Fibrosis Pulmonar IdiopáticaA phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Fibrosis Pulmonar Idiopática MedDRA version: 12.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim España S.A. | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Belgium;Spain;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| 172 | EUCTR2009-013788-21-BE (EUCTR) | 22/04/2010 | 08/03/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 17.0;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | SCS Boehringer Ingelheim Comm.V | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Portugal;France;Czech Republic;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Germany;United Kingdom;Italy | ||
| 173 | EUCTR2009-013788-21-FR (EUCTR) | 09/04/2010 | 08/03/2010 | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | A phase II open label, roll over study of the long term tolerability,safety and efficacy of oral BIBF 1120 in patients with IdiopathicPulmonary Fibrosis | Idiopathic Pulmonary Fibrosis MedDRA version: 12.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim France | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 300 | Phase 2 | Hungary;Portugal;United Kingdom;Czech Republic;Germany;Belgium;Bulgaria;France;Ireland;Spain;Italy;Greece | ||
| 174 | EUCTR2008-006054-17-IT (EUCTR) | 26/01/2010 | 22/10/2009 | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis. - MUSIC | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis. - MUSIC | Idiopathic Pulmonary Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10021240 | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: Macitentan | Actelion Pharamceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 156 | Germany;Slovenia;France;Spain;Italy;Sweden | |||
| 175 | EUCTR2009-011169-98-AT (EUCTR) | 26/11/2009 | 25/08/2009 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0;Classification code 10037400;Term: Pulmonary hypertension | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan | Gilead Sciences, Inc | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 176 | EUCTR2009-011169-98-DE (EUCTR) | 03/11/2009 | 06/08/2009 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0;Classification code 10037400;Term: Pulmonary hypertension | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan | Gilead Sciences, Inc | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | ||
| 177 | EUCTR2009-011169-98-GB (EUCTR) | 30/10/2009 | 01/09/2009 | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ARTEMIS-PH | Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis MedDRA version: 12.0;Classification code 10037400;Term: Pulmonary hypertension | Trade Name: Letairis INN or Proposed INN: Ambrisentan Trade Name: Letairis INN or Proposed INN: Ambrisentan | Gilead Sciences, Inc | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;Germany;United Kingdom;Italy;Austria | ||
| 178 | JPRN-UMIN000016045 | 2009/10/03 | 26/12/2014 | A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. - Combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis. | Idiopathic pulmonary fibrosis | Using Micro Air nebulizers and vibration mesh technology (NE-U07, Omron, Tokyo, Japan), patients receiving NAC combined with pirfenidone were treated twice daily with 352.4 mg of inhaled NAC, which was diluted with saline to a total volume of 6 mL for 48 weeks. Pirfenidone 1200-1800mg (control group) | Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo | ,NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 20 | Not selected | Japan |
| 179 | NCT00957242 (ClinicalTrials.gov) | October 2009 | 10/8/2009 | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis | AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (ACE-IPF) | Idiopathic Pulmonary Fibrosis | Drug: warfarin;Drug: placebo | Duke University | National Heart, Lung, and Blood Institute (NHLBI);Duke Clinical Research Institute | Terminated | 35 Years | 80 Years | All | 145 | Phase 3 | United States |
| 180 | EUCTR2009-011169-98-IT (EUCTR) | 22/09/2009 | 21/09/2009 | A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ND | A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - ND | Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension MedDRA version: 9.1;Level: LLT;Classification code 10021240 MedDRA version: 9.1;Classification code 10037400 | Trade Name: Letairis Trade Name: Letairis | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 3 | Czech Republic;United Kingdom;Germany;Italy;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 181 | EUCTR2008-004405-34-IE (EUCTR) | 08/09/2009 | 07/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 182 | EUCTR2008-006054-17-SE (EUCTR) | 12/08/2009 | 25/06/2009 | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | To evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis. MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: macitentan Product Code: ACT-064992 INN or Proposed INN: macitentan | Actelion Pharmaceuticals Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 156 | Germany;Slovenia;France;Spain;Italy;Sweden | |||
| 183 | EUCTR2008-004405-34-IT (EUCTR) | 03/08/2009 | 27/07/2009 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis MedDRA version: 12.0;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: VOLIBRIS INN or Proposed INN: Ambrisentan Trade Name: VOLIBRIS INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 184 | EUCTR2008-004405-34-GB (EUCTR) | 08/06/2009 | 28/04/2009 | ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | ARTEMIS-IPF: A Phase 3, Randomized, Double Blind, Placebo Controlled, Multi Center, Parallel Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 185 | EUCTR2008-004405-34-NL (EUCTR) | 04/06/2009 | 10/03/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 660 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 186 | JPRN-UMIN000007663 | 2009/06/01 | 05/04/2012 | Efficacy of inhaled N-acetylcysteine(NAC) on lung function and redox balance in idiopathic pulmonary fibrosis(IPF). | Idiopathic pulmonary fibrosis | inhaled NAC mono-therapy | Toho University Omori Medical CenterDepartment of Respiratory Medicine | NULL | Recruiting | 50years-old | 80years-old | Male and Female | 50 | Not selected | Japan | |
| 187 | EUCTR2008-006054-17-ES (EUCTR) | 20/05/2009 | 01/04/2009 | Estudio multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de Macitentan en pacientes con Fibrosis Pulmonar Idiopática.A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis. - MUSIC | Estudio multicéntrico, aleatorizado, de grupos paralelos, doble ciego, controlado con placebo para evaluar la eficacia, seguridad y tolerabilidad de Macitentan en pacientes con Fibrosis Pulmonar Idiopática.A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis. - MUSIC | Evaluar la eficacia, seguridad y tolerabilidad de Macitentan en pacientes con Fibrosis Pulmonar Idiopática. MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: Macitentan | Actelion Pharmaceuticals Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 156 | Germany;Slovenia;France;Spain;Italy;Sweden | |||
| 188 | EUCTR2008-006054-17-FR (EUCTR) | 29/04/2009 | 25/03/2009 | MUSIC: Macitentan USe in an Idiopathic pulmonary fibrosis Clinical studyA double-blind, randomized, placebo-controlled, multicenter, parallel group studyto evaluate the efficacy, safety, and tolerability of macitentan in patients withidiopathic pulmonary fibrosis - MUSIC | MUSIC: Macitentan USe in an Idiopathic pulmonary fibrosis Clinical studyA double-blind, randomized, placebo-controlled, multicenter, parallel group studyto evaluate the efficacy, safety, and tolerability of macitentan in patients withidiopathic pulmonary fibrosis - MUSIC | to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis | Product Name: ACT-064992 Product Code: ACT-064992 INN or Proposed INN: MACITENTAN | Actelion Pharmaceuticals Ltd. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 156 | Germany;Slovenia;France;Spain;Italy;Sweden | |||
| 189 | EUCTR2008-001281-86-BE (EUCTR) | 24/04/2009 | 15/10/2008 | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: CNTO888 Product Code: CNTO888 | Janssen Biologics B.V. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Belgium;Germany;Netherlands | ||
| 190 | EUCTR2007-001741-18-AT (EUCTR) | 02/04/2009 | 07/04/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 191 | EUCTR2008-006054-17-SI (EUCTR) | 31/03/2009 | 06/04/2009 | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | To evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis. MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Macitentan Product Code: ACT-064992 INN or Proposed INN: Macitentan | Actelion Pharmaceuticals Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 156 | Germany;Slovenia;France;Spain;Italy;Sweden | |||
| 192 | EUCTR2008-004405-34-ES (EUCTR) | 27/03/2009 | 28/01/2009 | ARTEMIS: A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Multi-Center, Parallel-Group,Event-Driven Study to Evaluate the Efficacy and Safety ofAmbrisentan in Subjects with Early Idiopathic PulmonaryFibrosis (IPF)ARTEMIS: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico, con grupos paralelos, en función de eventos, para evaluar la eficacia y seguridad de ambrisentan en sujetos con fibrosis pulmonar idiopática temprana (FPI). - ARTEMIS | ARTEMIS: A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Multi-Center, Parallel-Group,Event-Driven Study to Evaluate the Efficacy and Safety ofAmbrisentan in Subjects with Early Idiopathic PulmonaryFibrosis (IPF)ARTEMIS: Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico, con grupos paralelos, en función de eventos, para evaluar la eficacia y seguridad de ambrisentan en sujetos con fibrosis pulmonar idiopática temprana (FPI). - ARTEMIS | Idiopathic Pulmonary Fibrosis (IPF)fibrosis pulmonar idiopática temprana (FPI) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | ||
| 193 | EUCTR2008-004405-34-AT (EUCTR) | 13/03/2009 | 21/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 194 | EUCTR2008-004405-34-BE (EUCTR) | 09/03/2009 | 22/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 195 | NCT00879879 (ClinicalTrials.gov) | March 2009 | 10/4/2009 | Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis | Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project | Precancerous Condition | Drug: losartan | University of South Florida | National Cancer Institute (NCI) | Completed | 21 Years | N/A | All | 20 | N/A | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 196 | EUCTR2008-004405-34-FR (EUCTR) | 09/02/2009 | 16/03/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | United Kingdom;Germany;Czech Republic;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 197 | EUCTR2008-007168-40-IT (EUCTR) | 20/01/2009 | 09/03/2009 | Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosisSTUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008 | Use of 68Ga-DOTA-NOC for the evaluation of patients with Idiopathic pulmonary fibrosisSTUDY CODE: 68Ga-DOTA-NOC/ILD 01/2008 - 68Ga-DOTA-NOC/ILD01/2008 | patients with Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Gallium68-Dota-Noc | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 198 | EUCTR2008-001281-86-NL (EUCTR) | 14/01/2009 | 25/09/2008 | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: CNTO888 Product Code: CNTO888 | Centocor B.V. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | Germany;Netherlands;Belgium | ||
| 199 | EUCTR2007-001741-18-NL (EUCTR) | 17/09/2008 | 30/05/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| 200 | EUCTR2007-001741-18-IE (EUCTR) | 17/07/2008 | 12/03/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Spain;Ireland;Italy;Austria | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 201 | EUCTR2007-001741-18-FR (EUCTR) | 24/06/2008 | 04/02/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| 202 | EUCTR2007-001741-18-CZ (EUCTR) | 16/06/2008 | 18/04/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;United Kingdom;Czech Republic;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| 203 | EUCTR2007-007800-13-IT (EUCTR) | 11/06/2008 | 02/10/2008 | Studio di estensione in aperto sulla sicurezza a lungo termine del pirfenidone nei pazienti con fibrosi polmonare idiopatica (FPI) che hanno completato gli studi CAPACITY - ND | Studio di estensione in aperto sulla sicurezza a lungo termine del pirfenidone nei pazienti con fibrosi polmonare idiopatica (FPI) che hanno completato gli studi CAPACITY - ND | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone | INTERMUNE | NULL | Not Recruiting | Female: yes Male: yes | 750 | Germany;United Kingdom;Belgium;France;Spain;Ireland;Italy | |||
| 204 | EUCTR2007-007800-13-IE (EUCTR) | 04/06/2008 | 07/02/2008 | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone Other descriptive name: PIR, S-7701 | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | France;Belgium;Germany;Italy;United Kingdom;Ireland;Spain | ||
| 205 | NCT00690885 (ClinicalTrials.gov) | June 2008 | 3/6/2008 | Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis | Evaluation of Natural Human Interferon Alpha Lozenges in the Treatment of Chronic Cough in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF) | Pulmonary Disease, Chronic Obstructive;Pulmonary Fibrosis;Cough | Drug: interferon-alpha lozenges;Drug: placebo lozenges | Amarillo Biosciences, Inc. | Texas Tech University Health Sciences Center | Terminated | 40 Years | N/A | Both | 1 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 206 | EUCTR2007-007800-13-ES (EUCTR) | 26/05/2008 | 01/04/2008 | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY StudiesEstudio de extensión de etiqueta abierta de la seguridad a largo plazo de pirfenidona en pacientes con fibrosis pulmonar idiopática (FPI) que completan los estudios CAPACITY. - Open-Label Extension of Pirfenidone CAPACITY Studies | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY StudiesEstudio de extensión de etiqueta abierta de la seguridad a largo plazo de pirfenidona en pacientes con fibrosis pulmonar idiopática (FPI) que completan los estudios CAPACITY. - Open-Label Extension of Pirfenidone CAPACITY Studies | Idiopathic Pulmonary Fibrosis (IPF)Fibrosis pulmonar idiopática MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone Other descriptive name: PIR, S-7701 | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | France;Belgium;Spain;Ireland;Germany;Italy;United Kingdom | ||
| 207 | EUCTR2007-007800-13-DE (EUCTR) | 23/05/2008 | 21/02/2008 | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone Other descriptive name: PIR, S-7701 | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 750 | Phase 3 | France;Spain;Belgium;Ireland;Germany;Italy;United Kingdom | ||
| 208 | EUCTR2007-001741-18-DE (EUCTR) | 23/05/2008 | 03/11/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | France;Czech Republic;Belgium;Spain;Ireland;Austria;Netherlands;Germany;Italy;United Kingdom | |||
| 209 | EUCTR2007-007800-13-BE (EUCTR) | 15/05/2008 | 26/03/2008 | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone Other descriptive name: PIR, S-7701 | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 750 | France;Spain;Belgium;Ireland;Germany;Italy;United Kingdom | |||
| 210 | EUCTR2007-007800-13-FR (EUCTR) | 13/05/2008 | 29/02/2008 | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies - Open-Label Extension of Pirfenidone CAPACITY Studies | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 750 | France;Spain;Belgium;Ireland;Germany;Italy;United Kingdom | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 211 | EUCTR2006-002875-42-BG (EUCTR) | 12/05/2008 | 09/05/2008 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Pharma Ges mbH | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;France;Bulgaria;Spain;Ireland;Italy;Greece | |||
| 212 | EUCTR2007-001741-18-ES (EUCTR) | 21/04/2008 | 12/02/2008 | Estudio de extensión abierta en pacientes con Fibrosis Pulmonar Idiopática que hayan completado el protocolo AC-052-321 / BUILD 3 - BUILD-3-OL | Estudio de extensión abierta en pacientes con Fibrosis Pulmonar Idiopática que hayan completado el protocolo AC-052-321 / BUILD 3 - BUILD-3-OL | Fibrosis Pulmonar Idiopática (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| 213 | EUCTR2007-001741-18-BE (EUCTR) | 20/03/2008 | 14/03/2008 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321 / BUILD 3 - BUILD-3-OL | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | Actelion Pharmaceuticals Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| 214 | EUCTR2007-001741-18-IT (EUCTR) | 07/03/2008 | 23/03/2009 | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321/BUILD 3 - Build-3 OL | Open-label extension study in patients with Idiopathic Pulmonary Fibrosis who completed protocol AC-052-321/BUILD 3 - Build-3 OL | Idipathic Pulmonary Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10001892;Term: Alveolitis fibrosing | Trade Name: TRACLEER INN or Proposed INN: Bosentan | Actelion Registration Ltd | NULL | Not Recruiting | Female: yes Male: yes | 390 | Germany;Czech Republic;United Kingdom;Netherlands;Belgium;France;Ireland;Spain;Italy;Austria | |||
| 215 | EUCTR2006-002875-42-GR (EUCTR) | 22/01/2008 | 20/09/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 216 | EUCTR2006-002875-42-PT (EUCTR) | 11/01/2008 | 12/09/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim France | NULL | Not Recruiting | Female: yes Male: yes | 400 | Hungary;Portugal;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| 217 | EUCTR2006-002875-42-CZ (EUCTR) | 19/12/2007 | 10/07/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim Pharma Ges mbH | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Greece;Spain;Ireland;Italy;United Kingdom;France;Czech Republic;Hungary;Belgium;Bulgaria;Germany;Netherlands | |||
| 218 | EUCTR2007-001645-17-GB (EUCTR) | 04/12/2007 | 10/10/2007 | Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung Disease | Prevention of Established Pulmonary Hypertension in High Risk patients with Fibrotic Lung Disease – a double-blinded, randomised, placebo controlled trial with endothelin-1 receptor antagonist therapy - Prevention of Pulmonary Hypertension in Interstitial Lung Disease | Pulmonary hypertension in patients with interstitial lung disease. Specifically this trial looks at patients who have mild pulmonary hypertension, or are in an at-risk group to developing pulmonary hypertension, in the context of their interstitial lung disease. The interstitial lung diseases addressed include idiopathic pulmonary fibrosis and non-specific interstitial pneumonitis. MedDRA version: 9.1;Level: LLT;Classification code 10064911;Term: Pulmonary arterial hypertension | Trade Name: Tracleer Product Name: Tracleer | Royal Brompton and Harefield NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 219 | EUCTR2006-002875-42-HU (EUCTR) | 26/09/2007 | 27/06/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim RCV Ges mbH & Co KG | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| 220 | EUCTR2006-002875-42-IE (EUCTR) | 11/09/2007 | 12/06/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 221 | EUCTR2007-002324-15-GB (EUCTR) | 04/09/2007 | 17/03/2008 | The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC | The efficacy and safety of co-trimoxazole therapy in patients with idiopathic interstitial pneumonia - TIPAC | Idiopathic Interstitial Pneumonia MedDRA version: 9.1;Level: LLT;Classification code 10022619;Term: Interstitial pulmonary fibrosis | Trade Name: Septrin Product Name: co-trimoxazole Product Code: N/A INN or Proposed INN: N/A Other descriptive name: CO-TRIMOXAZOLE | University of East Anglia | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom | ||||
| 222 | EUCTR2006-002875-42-FR (EUCTR) | 23/08/2007 | 26/07/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim France SAS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| 223 | EUCTR2006-002875-42-ES (EUCTR) | 20/08/2007 | 19/06/2007 | Ensayo clínico randomizado, doble ciego, controlado con placebo de 12 meses de duración para evaluar el efecto de BIBF 1120 administrado por vía oral a dosis de 50 mg o.d., 50, 100 y 150 mg b.i.d. sobre la disminución anual de la Capacidad Vital Forzada (CVF) en pacientes con Fibrosis Pulmonar Idiopática, con una fase de extensión opcional hasta el final del ensayo.A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. | Ensayo clínico randomizado, doble ciego, controlado con placebo de 12 meses de duración para evaluar el efecto de BIBF 1120 administrado por vía oral a dosis de 50 mg o.d., 50, 100 y 150 mg b.i.d. sobre la disminución anual de la Capacidad Vital Forzada (CVF) en pacientes con Fibrosis Pulmonar Idiopática, con una fase de extensión opcional hasta el final del ensayo.A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. | Fibrosis pulmonar idiopática MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim España, S.A. | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Ireland;Spain;Italy;Greece | |||
| 224 | EUCTR2006-002875-42-BE (EUCTR) | 14/08/2007 | 24/05/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | SCS Boehringer Ingelheim Comm.V | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| 225 | NCT00517933 (ClinicalTrials.gov) | August 2007 | 15/8/2007 | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis;Hypertension, Pulmonary | Drug: Sildenafil Citrate;Other: Placebo | Duke University | National Heart, Lung, and Blood Institute (NHLBI);Pfizer | Completed | 18 Years | N/A | All | 180 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 226 | EUCTR2004-001876-37-DE (EUCTR) | 27/07/2007 | 27/02/2007 | BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFIT | BENEFIT-study: A randomized placebo controlled trial of anti-TNF-alpha chimeric monoclonal antibody ( infliximab) in idiopathic pulmonary fibrosis. - BENEFIT | Idiopathic Pulmonary Fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Remicade Product Name: Remicade | Academic Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 18 | Germany | |||
| 227 | EUCTR2006-002875-42-IT (EUCTR) | 17/07/2007 | 09/08/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. | idiopathic pulmonary fibrosis (IPF) MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Product Name: NA Product Code: BIBF 1120 ES | BOEHRINGER ING. | NULL | Not Recruiting | Female: yes Male: yes | 550 | Portugal;France;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Netherlands;Germany;United Kingdom;Italy | |||
| 228 | EUCTR2006-002875-42-NL (EUCTR) | 16/07/2007 | 04/06/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim bv | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;Hungary;United Kingdom;Germany;Netherlands;Belgium;Bulgaria;France;Spain;Ireland;Italy;Greece | |||
| 229 | EUCTR2006-002875-42-DE (EUCTR) | 06/07/2007 | 08/05/2007 | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. - Effect of orally administered BIBF 1120 on FVC decline in IPF | Idiopathic pulmonary fibrosis MedDRA version: 9.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: BIBF 1120 Product Code: BIBF 1120 | Boehringer Ingelheim | NULL | Not Recruiting | Female: yes Male: yes | 400 | Portugal;France;Hungary;Greece;Spain;Belgium;Ireland;Bulgaria;Netherlands;Germany;United Kingdom;Italy | |||
| 230 | EUCTR2006-001183-24-IE (EUCTR) | 30/04/2007 | 16/11/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 390 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 231 | EUCTR2006-001183-24-NL (EUCTR) | 06/03/2007 | 10/11/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 232 | EUCTR2006-001183-24-SK (EUCTR) | 26/02/2007 | 19/01/2007 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 390 | Phase 3 | France;Czech Republic;Slovakia;Spain;Belgium;Ireland;Denmark;Austria;Germany;Netherlands;Italy;United Kingdom | ||
| 233 | EUCTR2006-001183-24-DE (EUCTR) | 22/02/2007 | 01/12/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | France;Czech Republic;Spain;Belgium;Ireland;Denmark;Austria;Netherlands;Germany;Italy;United Kingdom | ||
| 234 | EUCTR2006-001183-24-ES (EUCTR) | 14/02/2007 | 07/04/2010 | Efectos de Bosentan sobre la morbilidad y mortalidad en pacientes con Fibrosis Pulmonar Idiopática- Estudio fase III, multicéntrico, randomizado, de grupos paralelos, doble ciego, controlado con placebo, secuencial por grupos, condicionado por acontecimientos.English:Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Efectos de Bosentan sobre la morbilidad y mortalidad en pacientes con Fibrosis Pulmonar Idiopática- Estudio fase III, multicéntrico, randomizado, de grupos paralelos, doble ciego, controlado con placebo, secuencial por grupos, condicionado por acontecimientos.English:Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Spanish:Fibrosis Pulmonar IdiopáticaEnglish:Idiopathic Pulmonary Fibrosis MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 600 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Ireland;Spain;Italy;Austria | ||
| 235 | EUCTR2006-001183-24-CZ (EUCTR) | 07/02/2007 | 21/12/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Germany;United Kingdom;Czech Republic;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 236 | EUCTR2006-001183-24-DK (EUCTR) | 24/01/2007 | 12/12/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 390 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Belgium;Denmark;France;Spain;Ireland;Italy;Austria | ||
| 237 | EUCTR2006-001183-24-AT (EUCTR) | 10/01/2007 | 11/12/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 238 | NCT00563212 (ClinicalTrials.gov) | January 2007 | 21/11/2007 | A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis | A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Drug: aerosol interferon-gamma | NYU Langone Health | National Center for Research Resources (NCRR);Stony Brook University;Philips Respironics | Completed | 40 Years | 75 Years | All | 12 | Phase 1 | United States |
| 239 | EUCTR2006-001183-24-BE (EUCTR) | 12/12/2006 | 14/11/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer Product Name: Bosentan Product Code: Ro 47-0203 INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Not Recruiting | Female: yes Male: yes | 460 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | ||
| 240 | EUCTR2006-001183-24-IT (EUCTR) | 11/12/2006 | 05/01/2007 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD 3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD 3 | Patients with Idiopathic pulmonary fibrosis Level: PTClassification code 10037383 | Trade Name: TRACLEER | Actelion Pharmaceuticals LTD | NULL | Not Recruiting | Female: yes Male: yes | 390 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 241 | EUCTR2006-002174-22-DE (EUCTR) | 08/11/2006 | 23/08/2006 | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Influence of inhaled Aviptadil on CCL18 serum concentrations in patients with pulmonary fibrosis - Inhaled Aviptadil in pulmonary fibrosis | Pulmonary Fibrosis categorized as UIP or NSIP | Product Name: Aviptadil, 66 microgram/mL Other descriptive name: Vasoactive intestinal peptide | Mondobiotech Laboratories Anstalt | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Germany | ||||
| 242 | NCT00463983 (ClinicalTrials.gov) | October 2006 | 18/4/2007 | Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide | Phase 2 Study of Long Acting Octreotide in Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: octreotide | Institut National de la Santé Et de la Recherche Médicale, France | NULL | Completed | 40 Years | N/A | Both | 25 | Phase 1;Phase 2 | France |
| 243 | EUCTR2006-000252-41-IT (EUCTR) | 27/09/2006 | 30/08/2006 | A randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirferidone in patients with Idiopathic Pulmonary Fibrosis - ND | A randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-Arm Study of the Safety and Efficacy of Pirferidone in patients with Idiopathic Pulmonary Fibrosis - ND | Idiopathic pulmonary fibrosis IPF ICD X J84.1other interstitial pulmonary MedDRA version: 6.1;Level: PT;Classification code 10037383 | Product Name: PIR, S-7701 | INTERMUNE | NULL | Not Recruiting | Female: yes Male: yes | 325 | Phase 3 | United Kingdom;Italy | ||
| 244 | EUCTR2006-000138-11-ES (EUCTR) | 31/07/2006 | 18/05/2006 | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisEstudio aleatorio, a doble ciego, controlado con placebo, de fase 3 sobre la seguridad y eficacia de Pirfenidona en pacientes con fibrosis pulmonar idiopática | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisEstudio aleatorio, a doble ciego, controlado con placebo, de fase 3 sobre la seguridad y eficacia de Pirfenidona en pacientes con fibrosis pulmonar idiopática | Idiopathic Pulmonary Fibrosis (IPF)Fibrosis Pulmonar Idiopática | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone | InterMune, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 260 | Phase 3 | Czech Republic;Germany;Belgium;Ireland;Spain | ||
| 245 | EUCTR2006-000138-11-DE (EUCTR) | 29/06/2006 | 16/02/2006 | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 3 | Czech Republic;Germany;Belgium;Spain;Ireland | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 246 | EUCTR2006-000138-11-BE (EUCTR) | 27/06/2006 | 10/03/2006 | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 3 | Czech Republic;Germany;Belgium;Spain;Ireland | ||
| 247 | EUCTR2006-000138-11-CZ (EUCTR) | 25/05/2006 | 06/04/2006 | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Product Name: Pirfenidone INN or Proposed INN: Pirfenidone | InterMune, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 3 | Germany;Czech Republic;Belgium;Spain;Ireland | ||
| 248 | NCT00518310 (ClinicalTrials.gov) | May 2005 | 16/8/2007 | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study | Idiopathic Pulmonary Fibrosis | Drug: Placebo;Drug: AZAPRED | Thorax National Institute | Sociedad Chilena de Enfermedades Respiratorias;Servicio de Salud Metropolitano Oriente, Ministerio de Salud de Chile | Recruiting | 45 Years | 79 Years | Both | 100 | N/A | Chile |
| 249 | EUCTR2004-000029-31-IE (EUCTR) | 28/01/2005 | 08/12/2004 | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Interferon gamma-Ib in patients with Idiopathic Pulmonary Fibrosis The INSPIRE Trial - International Study of Survival outcomes in IPF with Interferon gamma-1b) - INSPIRE | Idiopathic Pulmonary Fibrosis (IPF) | Trade Name: Immukin Product Name: Interferon gamma-1b | InterMune | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | Ireland | ||
| 250 | EUCTR2004-001261-17-IE (EUCTR) | 28/01/2005 | 08/12/2004 | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis | An Open-Label Study of the Safety of Subcutaneous Recombinant Interferon gamma-1b in Patients with Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis (IPF) | Trade Name: Immukin Product Name: Interferon gamma-1b | InterMune | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | Ireland | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 251 | NCT00352482 (ClinicalTrials.gov) | November 2004 | 13/7/2006 | Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension | Sildenafil Treatment in Patients With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension - a Pilot Cross-over Study | Pulmonary Fibrosis;Hypertension, Pulmonary | Drug: Sildenafil (50 mg) | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 19 Years | N/A | Both | 20 | Phase 2 | United States |
| 252 | NCT00262405 (ClinicalTrials.gov) | January 2001 | 12/9/2005 | Zileuton for the Treatment of Idiopathic Pulmonary Fibrosis | Phase II Trial of Zileuton Compared to Azathioprine/Prednisone for the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: zileuton;Drug: azathioprine/prednisone | University of Michigan | National Institutes of Health (NIH) | Completed | 35 Years | 80 Years | Both | 44 | Phase 2 | United States |
| 253 | NCT00639496 (ClinicalTrials.gov) | March 2000 | 13/3/2008 | Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) | Pulmonary Fibrosis | Drug: n-acetylcysteine;Drug: placebo | Zambon SpA | NULL | Completed | 18 Years | 75 Years | Both | 184 | Phase 3 | Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom |
| 254 | EUCTR2008-006054-17-DE (EUCTR) | 05/03/2009 | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis - MUSIC | To evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis. MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Product Name: macitentan Product Code: ACT-064992 INN or Proposed INN: macitentan | Actelion Pharmaceuticals Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 156 | France;Slovenia;Spain;Germany;Italy;Sweden | ||||
| 255 | EUCTR2006-001183-24-FR (EUCTR) | 28/11/2006 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study - BUILD-3 | Idiopathic Pulmonary Fibrosis (IPF) MedDRA version: 8.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Tracleer INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer Trade Name: Tracleer INN or Proposed INN: BOSENTAN Other descriptive name: Tracleer | ACTELION PHARMACEUTICALS LTD | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 390 | Phase 3 | Czech Republic;Germany;United Kingdom;Netherlands;Denmark;Belgium;France;Spain;Ireland;Italy;Austria | |||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 256 | EUCTR2008-004405-34-DE (EUCTR) | 14/01/2009 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event-Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Early Idiopathic Pulmonary Fibrosis (IPF) - ARTEMIS-IPF | Idiopathic pulmonary fibrosis (IPF) MedDRA version: 9.1;Level: LLT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis | Trade Name: Letairis 5 mg INN or Proposed INN: Ambrisentan Trade Name: Letairis 10 mg INN or Proposed INN: Ambrisentan | Gilead Sciences Incorporated | NULL | Not Recruiting | Female: yes Male: yes | 660 | Phase 3 | France;Czech Republic;Spain;Belgium;Ireland;Austria;Netherlands;Germany;Italy;United Kingdom | |||
| 257 | JPRN-JapicCTI-142452 | 21/02/2014 | A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis | A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Intervention name : Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor Dosage And administration of the intervention : Low Dose, Biological: tralokinumab cohort 1, High Dose, Biological: tralokinumab cohort 2 | AstraZeneca | MedImmune LLC | 50 | BOTH | Phase 2 | NULL |